Literature DB >> 33112548

CyclinA1 Promoter Methylation in Self-Sampling Test.

Shina Oranratanaphan1, Malika Kengsakul2, Surang Triratanachat1, Nakarin Kitkumthorn3, Apiwat Mutirangura4, Wichai Termrungruanglert1.   

Abstract

BACKGROUND: Self sampled HPV testing is a cervical cancer screening method . However, cytology in self-sampled specimen cannot be used as a triage test.  Therefore, other methods for triage should be considered. CyclinA1 (CCNA1) promoter methylation has strong association with cervical precancerous and cancerous lesion. The objective of this study was to compare the diagnostic value of CCNA1 and self-sampled specimen for detecting high-grade cervical intraepithelial lesions or worse (CIN2+).
MATERIALS AND METHODS: A cross sectional study was conducted. Women with abnormal cytology or positive for high risk HPV (hrHPV) indicated for colposcopic examination were enrolled.  Self-collected sampling for hrHPV DNA (SS-HPV) and CCNA1 were performed. hrHPV DNA testing was done by Cobas 4800 method. CCNA1 promoter methylation was detected by CCNA1 duplex methylation specific PCR. Histopathologic result as CIN2+ obtaining from colposcopic directed biopsy or excisional procedure  was considered as positive a gold standard. The results of hrHPV and CCNA1 were reported as positive or negative. Sensitivity specificity, positive predictive value, and negative predictive value of SS-HPV and CCNA1 were calculated by comparing the results with the gold standard.
RESULTS: Two hundreds and eighty women were recruited. High-grade cervical lesions and cervical cancer (CIN2+) were diagnosed in 21.8% (61 cases) of the patients. The most common type of hrHPV was non 16, 18 subtype, followed by HPV16 and 18. CCNA1 was positive in 13 patients out of whom, twelve were CIN2+. Sensitivity of CCNA1 was 19.7 % and its  specificity and accuracy were 99.5% and 82.14%, respectively.  The sensitivity of SS-HPV was 70.5%, and its  specificity and accuracy were 39.2% and 43.3%, respectively.
CONCLUSION: Due to high specificity and positive predictive value of CCNA1, it can be used as alarming sign of having high-grade cervical intraepithelial lesions, especially in patient who has positive hrHPV DNA test based on self-collected sampling.<br />.

Entities:  

Keywords:  CCNA1; CIN2+; CyclinA1 promotor methylation; cervical cancer screening; self-sampling

Mesh:

Substances:

Year:  2020        PMID: 33112548      PMCID: PMC7798151          DOI: 10.31557/APJCP.2020.21.10.2913

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  17 in total

1.  Self-Collected Samples in Cervical Cancer Screening: Results of HPV and Pap Self-Collected Samples Compared to Physician-Obtained Specimens.

Authors:  Bernhard Reinhold Mangold
Journal:  Acta Cytol       Date:  2019-04-29       Impact factor: 2.319

2.  Comparison of detection rate of high risk HPV infection between self-collected HPV testing and clinician-collected HPV testing in cervical cancer screening.

Authors:  Pattiya Nutthachote; Shina Oranratanaphan; Wichai Termrungruanglert; Surang Triratanachat; Arkom Chaiwongkot; Fern Baedyananda; Parvapan Bhattarakosol
Journal:  Taiwan J Obstet Gynecol       Date:  2019-07       Impact factor: 1.705

Review 3.  Triage of HPV positive women in cervical cancer screening.

Authors:  Nicolas Wentzensen; Mark Schiffman; Timothy Palmer; Marc Arbyn
Journal:  J Clin Virol       Date:  2015-11-28       Impact factor: 3.168

4.  Acceptability of self-sampling HPV testing among Thai women for cervical cancer screening.

Authors:  Shina Oranratanaphan; Wichai Termrungruanglert; Nipon Khemapech
Journal:  Asian Pac J Cancer Prev       Date:  2014

5.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

6.  Correlation of CCNA1 promoter methylation with malignant tumors: a meta-analysis introduction.

Authors:  Bin Yang; Shuai Miao; Le-Ning Zhang; Hong-Bin Sun; Zhe-Nan Xu; Chun-Shan Han
Journal:  Biomed Res Int       Date:  2015-01-15       Impact factor: 3.411

7.  Cyclin A1 promoter hypermethylation in human papillomavirus-associated cervical cancer.

Authors:  Nakarin Kitkumthorn; Pattamawadee Yanatatsanajit; Sorapop Kiatpongsan; Chureerat Phokaew; Surang Triratanachat; Prasert Trivijitsilp; Wichai Termrungruanglert; Damrong Tresukosol; Somchai Niruthisard; Apiwat Mutirangura
Journal:  BMC Cancer       Date:  2006-03-08       Impact factor: 4.430

8.  A promising DNA methylation signature for the triage of high-risk human papillomavirus DNA-positive women.

Authors:  Alfred Hansel; Daniel Steinbach; Christiane Greinke; Martina Schmitz; Juliane Eiselt; Cornelia Scheungraber; Mieczyslaw Gajda; Heike Hoyer; Ingo B Runnebaum; Matthias Dürst
Journal:  PLoS One       Date:  2014-03-19       Impact factor: 3.240

9.  Economic evaluation of HPV DNA test as primary screening method for cervical cancer: A health policy discussion in Greece.

Authors:  Anastasios Skroumpelos; Theodoros Agorastos; Theodoros Constantinidis; Kimon Chatzistamatiou; John Kyriopoulos
Journal:  PLoS One       Date:  2019-12-12       Impact factor: 3.240

10.  Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials.

Authors:  Guglielmo Ronco; Joakim Dillner; K Miriam Elfström; Sara Tunesi; Peter J F Snijders; Marc Arbyn; Henry Kitchener; Nereo Segnan; Clare Gilham; Paolo Giorgi-Rossi; Johannes Berkhof; Julian Peto; Chris J L M Meijer
Journal:  Lancet       Date:  2013-11-03       Impact factor: 79.321

View more
  1 in total

1.  Worldwide initiatives to eliminate cervical cancer.

Authors:  Sarikapan Wilailak; Malika Kengsakul; Sean Kehoe
Journal:  Int J Gynaecol Obstet       Date:  2021-10       Impact factor: 4.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.